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Abstract
TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that participates in HIV-1 pathogenesis
through the depletion of CD4+ T cells. TRAIL is expressed on the cell membrane of peripheral immune cells and can be
cleaved into a soluble, secreted form. The regulation of TRAIL in macrophages during HIV-1 infection is not completely
understood. In this study, we investigated the mechanism(s) of TRAIL expression in HIV-1-infected macrophages, an
important cell type in HIV-1 pathogenesis. A human monocyte-derived macrophage (MDM) culture system was infected
with macrophage-tropic HIV-1ADA, HIV-1JR-FL, or HIV-1BAL strains. TRAIL, predominantly the membrane-bound form,
increased following HIV-1 infection. We found that HIV-1 infection also induced interferon regulatory factor (IRF)-1, IRF-7
gene expression and signal transducers and activators of transcription 1 (STAT1) activation. Small interfering RNA
knockdown of IRF-1 or IRF-7, but not IRF-3, reduced STAT1 activation and TRAIL expression. Furthermore, the upregulation
of IRF-1, IRF-7, TRAIL, and the activation of STAT1 by HIV-1 infection was reduced by the treatment of type I interferon (IFN)-
neutralizing antibodies. In addition, inhibition of STAT1 by fludarabine abolished IRF-1, IRF-7, and TRAIL upregulation. We
conclude that IRF-1, IRF-7, type I IFNs, and STAT1 form a signaling feedback loop that is critical in regulating TRAIL
expression in HIV-1-infected macrophages.
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Introduction
TNF-related apoptosis-inducing ligand (TRAIL) is a member of
the TNF superfamily and an important immune regulatory factor
capable of inducing apoptosis [1–3]. TRAIL is expressed on the
cell membrane of CD4+ T lymphocytes, natural killer cells, and
mononuclear phagocytes (monocytes and macrophages) and can
be cleaved into a soluble, secreted form [4]. The plasma levels of
TRAIL are increased in HIV-1-infected patients compared to
uninfected individuals, and patients receiving anti-retroviral
therapy show decreased plasma TRAIL levels that correlate with
reduced viral load [5]. Increased TRAIL expression is an
important contributor to HIV-1-mediated apoptosis in bystander
CD4+ T cells [6–9]. Furthermore, recombinant human TRAIL
has been found to induce apoptosis in HIV-1-infected macro-
phages and cultured neurons as we have previously reported
[10,11]. Although the apoptotic signaling events of TRAIL have
been studied extensively, including our recent work [10–13], the
upstream molecular stimuli, particularly those that are responsible
for HIV-1-mediated TRAIL upregulation, remain unclear.
Macrophage (M)-tropic HIV strains preferentially infect mono-
nuclear phagocytes, a cell type critical to HIV-1 replication in the
disease [14,15]. Infected mononuclear phagocytes disseminate virus
to lymph nodes where CD4+ T lymphocytes become infected and to
tissues, including the lung and central nervous system, where they
serve as viral reservoirs [16–19]. TRAIL expression is induced by
interferon (IFN)-a, -b, and -c in monocytes [20], by IFN-a and -b
but not -c, in Jurkat cells [21], and by IFN-b in CD4+ T cells [22].
However, limited information on how HIV-1 regulates TRAIL in
mononuclear phagocytes has been reported to date.
Type I IFNs IFN-a and -b are primarily induced by
plasmacytoid dendritic cells (pDCs) and in a lower amount by
monocytes and macrophages following viral infection [23,24]. All
type I IFNs interact with the IFN-a receptor (IFNAR), which
appears to couple to a uniform signal transduction cascade (for
review, see [25]). IFN-a/b binding triggers receptor dimerization
and activation, leading to phosphorylation of a tyrosine residue on
IFNAR. This phosphorylation stimulates the JAK/STAT pathway
leading to the formation of signal transducers and activators of
transcription 1 (STAT1) homodimers as well as heterodimers with
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STAT3 [26]. Activated STAT dimers translocate to the nucleus
and bind to interferon stimulated response elements of the
promoters for IFN-stimulated genes(for review, see [27]), including
TRAIL [28].
IFN regulatory factors (IRFs) are a family of transcription factors
that regulate the antiviral response. IRFs are closely related to type I
IFNs and consist of nine mammalian proteins characterized by an
amino-terminal DNA-binding domain [29]. Gene knockout of IRF-
1, IRF-3, or IRF-7 results in high susceptibility to infectious agents
[30–32]. IRF-1 and IRF-7 were identified by their ability to induce
the transcription of type I IFN and IFN-inducible genes, and both
are induced by HIV-1 [33–36]. IRF-1, IRF-3, and IRF-7 are
constitutively expressed in most cell types, whereas the expression of
IRF-1 and IRF-7 are more inducible following exposure of cells to
IFNs [37]. In addition, IRF-1, IRF-3, and IRF-7 have been linked to
TRAIL transcription [38–41]. However, the exact role of IRFs in
the promotion of TRAIL expression, especially in mononuclear
phagocytes, remains unclear.
Using a monocyte-derived macrophage (MDM) model, we
investigated how TRAIL expression is upregulated in macrophag-
es during HIV-1 infection. Our results demonstrated that
upregulation of TRAIL expression in HIV-1-infected MDM was
predominantly membrane-associated. HIV-1 infection induced
IRF-1 and IRF-7 gene expression and STAT1 phosphorylation in
macrophages. Small interfering RNA (siRNA) knockdown of IRF-
1 or IRF-7 but not IRF-3 reduced STAT1 activation and TRAIL
expression. Treatment with various cytokines identified IFNs as
the critical factors stimulating TRAIL expression. The upregula-
tion of IRF-1, IRF-7, and TRAIL, and the activation of STAT1
by HIV-1 infection was reduced by the treatment of type I
interferon neutralizing antibodies. In addition, inhibition of
STAT1 by fludarabine abolished IRF-1, IRF-7, and TRAIL
upregulation. These data suggest that IRF-1, IRF-7, Type I IFNs,
and STAT1 form a signaling feedback loop and cooperatively
regulate TRAIL expression in macrophages during HIV-1
infection. Understanding the signaling events in HIV-1-infected
macrophages may lead to the development of new therapies to
alleviate macrophage-mediated HIV-1 pathogenesis by reducing
the expression of death ligand TRAIL.
Materials and Methods
Reagents
Recombinant proteins, neutralizing antibodies, and chemicals
were obtained as follows: IL-1b, TNF-a, IFN-c, IFN-b neutral-
izing antibody, and Mouse IgG1 (R&D Systems, Minneapolis,
MN); IFN-a, IFN-b, and IFN-a neutralizing antibody (PBL
Interferon Source, Piscataway, NJ); Aidovudine (AZT, HIV-1
reverse transcriptase inhibitor), fludarabine, and lipopolysaccha-
ride (LPS) (Sigma-Aldrich, St. Louis, MO).
Monocyte cell culture and HIV-1 infection
Human monocytes were isolated from peripheral blood
mononuclear cells of HIV-1, -2, and hepatitis B seronegative
donors after leukopheresis and counter current centrifugal
elutriation [42]. Monocytes were cultured as adherent monolayers
at a density of 1.16106 cells/well in 24-well plates and cultivated
in Dulbecco’s modified Eagles medium (DMEM, GIBCO
Invitrogen Corp, Carlsbad, CA) with 10% heat-inactivated pooled
human serum (Cambrex Bio Science, Walkersville, MD), 50 mg/
ml gentamicin, 10 mg/ml ciprofloxacin (Sigma-Aldrich, St. Louis,
IL), and 1000 U/ml highly purified recombinant human macro-
phage colony stimulating factor (M-CSF) (a generous gift from the
Wyeth Institute, Cambridge, MA).
Seven days after plating, MDM were infected with HIV-1 strains
ADA, BAL, or JR-FL at a multiplicity of infection (MOI) of 0.1. On
the second day after infection, media were removed and substituted
with MDM culture media (DMEM with 10% heat-inactivated
pooled human serum, 50 mg/ml gentamicin, and 10 mg/ml
ciprofloxacin) [42]. Stock virus was screened for mycoplasma and
endotoxin using hybridization and Limulus amebocyte lysate assays,
respectively. Five days after infection, cells were changed to 0.5 ml/
well fresh medium for 24 hours. Culture supernatants were obtained
and subsequently stored at 280uC until assayed. Filtration of
supernatants was performed with Amicon Ultra 100 K nominal
molecular weight limit devices (Millipore, Billerica, MA).
Measurements of HIV-1 reverse transcriptase (RTase)
activity
HIV-1 RTase activity was determined in triplicate samples of
cell culture fluids. Supernatant (10 ml) was incubated in a reaction
mixture of 0.05% Nonidet P-40, 10 mg of poly(A)/ml, 0.25 mg of
oligo(dT)/ml, 5 mM dithiothreitol, 150 mM KCl, 15 mM MgCl2,
and [3H]TTP in Tris-HCl buffer (pH 7.9) for 24 h at 37uC.
Radiolabeled nucleotides were precipitated with cold 10%
trichloroacetic acid on filter paper plates in an automatic cell
harvester and washed with 95% ethanol. Radioactivity was
estimated by liquid scintillation spectroscopy [18].
RNA extraction and TaqMan real-time RT-PCR
Total RNA was isolated with TRIzol Reagent (Invitrogen) and
RNeasyMini Kit (QIAGEN Inc., Valencia, CA). Assays-on-Demand
primers for human TRAIL (ID#, Hs00234356_m1), IRF-1 (ID#,
Hs00971965_m1), IRF-3 (ID#, Hs00155574_m1), IRF-7 (ID#,
Hs00185375_m1), and human GAPDH (ID#, 4310884E) were
purchased fromApplied Biosystems, Inc. (Foster City, CA). Real-time
reverse-transcription polymerase chain reaction (RT-PCR) was
carried out using the one-step quantitative TaqMan Real-time RT-
PCR system (Applied Biosystems). TRAIL, IRF-1, IRF-3, and IRF-7
mRNA levels were determined and standardized with a GAPDH
internal control, and normalized to uninfected cells using compar-
ative DDCT method. All primers used in the study were tested for
amplification efficiencies and the results were similar.
TRAIL and CCL5 ELISA
Supernatants from MDM were collected for TRAIL and CCL5
determination by ELISA (R&D Systems) as described previously
[10,43]. The sensitivity of soluble TRAIL and RANTES ELISA is
10 pg/ml. To assess concentrations of TRAIL in cell lysates of
macrophages, we replaced the cell lysis buffer in the ELISA system
with a lysis buffer from Pierce (Rockford, IL), which provides
better lysis effect for membrane protein; the sensitivity for this
assay was 100 pg/ml for TRAIL.
Western blot analysis
Cell lysates from macrophages were prepared with M-PER
Mammalian Protein Extraction Buffer (Pierce). Protein concen-
tration was determined using the BCA Protein Assay Kit (Pierce).
Protein (30 mg) was electrophoresed on pre-cast 8% SDS-PAGE
and transferred to an Immuno-Blot PVDF membrane (Bio-Rad,
Hercules, CA). Antibodies specific for Phospho-STAT1 at tyrosine
701, total STAT1, IRF-3, and retinoic acid-inducible gene I (RIG-
I) were from Cell Signaling Technology, Inc. (Danvers, MA).
Loading control b-actin proteins were detected using anti-b-actin
(Sigma-Aldrich) antibodies. Membranes were treated overnight
with primary antibody at 4uC followed by a horseradish
peroxidase-ligand secondary anti-rabbit (Cell Signaling Technol-
HIV-1, TRAIL, and Macrophage
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ogy) or anti-mouse (Cell Signaling Technology) antibody for
1 hour at room temperature. Antigen-antibody complexes were
visualized by enhanced chemiluminescence (Amersham Biosci-
ences, Piscataway, NJ) and captured with CL-X PosureTM Film
(Pierce). For data quantification the films were scanned with a
CanonScan 9950F scanner; the acquired images were then
analyzed on a Macintosh computer using the public domain
NIH image program (http://rsb.info.nih.gov/nih-image/).
siRNA transfection
Pre-designed siRNA duplexes for IRF-1 (ID#, 115266), IRF-3
(ID#, 115222), or IRF-7 (ID#, 115481) were synthesized by Ambion
Inc. (Austin, Texas). Two days post-infection MDM were transfected
with 120 nM siRNA duplex for 48–96 hours in the presence of
siIMPORTER (Upstate Cell Signaling Solutions, Charlottesville,
VA) according to the manufacturer’s instructions. A validated
Silencer Negative Control #1 siRNA (Ambion Inc.) was also
transfected at the same concentration as IRFs siRNA. To evaluate
transfection efficiency, control and HIV-1-infected MDM were
transfected with Silencer FAM-labeled Negative Control #1 siRNA
(green fluorescence tagged siRNA) (Ambion Inc.). At 48 hours post-
transfection, cells were incubated with Hoechst 33342 (Sigma) for
nuclear staining, transfected and total cells were counted.
Immunocytochemical assays
Human MDM were plated on 15 mm cover slips in 24-well
plates. Five days after infection, cells were fixed with 4%
paraformaldehyde at room temperature then incubated with
methanol for 20 minutes at 220uC. Fixed cells were blocked with
3% BSA in PBS and then incubated with primary antibodies to
TRAIL (human TRAIL specific polyclonal, Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA) mixed with antibody to p24
(monoclonal mouse anti-human p24, IgG, DAKO Corp, Carpin-
teria, CA) at 4uC overnight. Normal mouse or rabbit IgG with
matched isotype were used as negative controls for the staining.
Cultures were washed and secondary antibodies, anti-mouse IgG
(coupled with green dye, Alexa Flour 488, Molecular Probes,
Eugene, Oregon), or anti-rabbit IgG (coupled with a info-red dye,
Alexa Fluor 647, Molecular Probes) were added for 1 hour at
room temperature. Nuclei DNA were labeled with Hoechst 33342
(Sigma-Aldrich) for 10 minutes at room temperature. Cover slips
were mounted on glass slides with mounting medium (Sigma-
Aldrich). Triple immunostaining was examined by a Bio-Rad
MRC1024ES lASER scanning confocal microscope using a triple
laser line and simultaneous triple display mode of the Bio-Rad
LaserSharp imaging program.
Statistical tests
Data were analyzed as means6standard deviation (SD) unless
otherwise specified. The data were evaluated statistically by the
analysis of variance (ANOVA), followed by the Tukey-test for
paired observations. Significance was considered with a p value
less than 0.05. All experiments were performed with at least three
donors to account for any donor specific differences. Assays were
performed at least three times in triplicate or quadruplicate.
Results
HIV-1-induced upregulation of TRAIL expression is
predominantly membrane-associated and dependent on
productive HIV-1 infection
Upregulation of TRAIL expression by HIV-1-infected macro-
phages has been previously reported [7,10]; our current study
investigated the mechanisms behind this upregulation. We used
macrophage-tropic HIV-1 strains HIV-1ADA, HIV-1JR-FL, and
HIV-1BAL to infect human MDM. Five days after infection,
culture supernatants were collected and HIV-1 viral infectivity
was determined by the HIV-1 RTase activity assay. HIV-1ADA
and HIV-1BAL demonstrated higher infectivity as compared to
HIV-1JR-FL (Fig. 1A). AZT, a HIV-1 reverse transcriptase
inhibitor, completely blocked HIV-1 reverse transcription of all
strains tested (Fig. 1A). The investigated macrophage-tropic viral
strains all strongly upregulated TRAIL expression levels as
indicated by real-time RT-PCR, and this upregulation was then
blocked by reverse transcriptase inhibitor AZT (Fig. 1B). HIV-
1ADA strain was used thereafter and referred to as HIV-1.
To determine the effects of HIV-1 infection on TRAIL mRNA
and protein levels in MDM, we used real-time RT-PCR and an
ELISA-based detection system, respectively. As the infection
progressed from day 1 through day 7 the HIV-1 RTase activity
continued to increase (Fig. 1C). TRAIL mRNA expression was not
significantly changed at 1 day post-infection but was significantly
upregulated on days 3, 5, and 7 as compared to uninfected control
(Fig. 1D). TRAIL mRNA upregulation peaked at day 5 and was
7.3-fold higher in HIV-infected MDM as compared to uninfected
control. To determine the protein levels of TRAIL, whole-cell
lysates were collected 1, 3, 5, and 7 days after HIV-1 infection and
then subjected to ELISA detection. TRAIL protein levels
increased starting at 3 days and peaked at 5 days after infection
(Fig. 1E). After 7 days of infection, cultures underwent significant
macrophage cell death (approximately 50% loss in cell viability,
data not shown) and the protein level of TRAIL decreased
accordingly. TRAIL ELISA was also used to measure soluble
TRAIL protein within the HIV-1-infected and uninfected MDM
supernatants and no significant changes in TRAIL concentrations
were found (Fig. 1F). These results indicate TRAIL upregulation is
associated with membrane-bound TRAIL rather than the soluble
form.
We further specified that the membrane-bound form of TRAIL
is upregulated following HIV-1 infection by using immunocyto-
chemistry and confocal microscopy. During the progression of
MDM HIV-1 infection, the percentage of infected cells continued
to increase. At days 5, staining of uninfected MDM was positive
for TRAIL (Fig. 2A, D) and negative for p24 (Fig. 2B, D). HIV-1-
infected MDM culture showed a dramatic increase in TRAIL
staining (Fig. 2E, H), particularly those MDM that were adjacent
to p24-positive multinucleated giant cells expressed high levels of
TRAIL surface staining (Fig. 2E, F, H). Thus, it is likely that
uninfected macrophages increase TRAIL protein synthesis in
response to diffusible factor(s) released by infected cells.
HIV-1 infection induces IRF-1, IRF-7 gene expression and
STAT1 phosphorylation in macrophages
To determine the molecular mechanisms that mediate TRAIL
expression, we studied the signaling pathways in the macrophage
innate immunity that respond to HIV-1 infection. First, we
examined the regulation of the IRF transcription factors after
HIV-1 infection of MDM. The expression levels of IRF-1 and
IRF-7 increased upon HIV-1 infection and the increase occurred
as early as 3 days after infection (Fig. 3A, C). In contrast, the
expression levels of IRF-3 remained the same except at 5 days
after infection, where an average 26% reduction in IRF-3
expression was found (Fig. 3B). We also treated MDM with
IFN-a and observed an increase in IRF-1, IRF-3, and IRF-7 gene
expression, confirming all these genes are IFN-stimulated genes
(Fig. 3A–C).
HIV-1, TRAIL, and Macrophage
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IRF-1 and IRF-7 are able to induce the production of type I
IFNs, which primarily activate STAT1/STAT2 signaling mole-
cules. We next determined the phosphorylation at Tyr701 of
STAT1 that is obligatory for STAT1 activation. HIV-1 induced
STAT1 phosphorylation 3 days after infection, and the phos-
phorylation persisted for 4 additional days (Fig. 3D, E). HIV-1
infection also increased total STAT1 at 5 and 7 days after infection
(Fig. 3D, F). Together, these data demonstrate that HIV-1
infection induces activation of STAT1 through phosphorylation
of Tyr701 as well as an increase in total STAT1 protein levels in
MDM. The similar kinetics of IRF-1, IRF-7 expression, STAT1
activation, and TRAIL production indicates these molecules may
associate with the same signaling pathway.
siRNA knockdown of IRF-1 and IRF-7 reduces TRAIL
expression in HIV-1-infected macrophages
To further elucidate whether increased levels of IRFs mediate
the increase in TRAIL transcription, we transfected IRF-1, IRF-3
or IRF-7 siRNA, and a nonspecific siRNA as a control in MDM
cultures. siRNA was successfully delivered into both control and
HIV-1-infected MDM, as demonstrated by FAM-labeled control
Figure 1. TRAIL expression in human macrophages increases when infected with HIV-1. A–B. Human MDM were infected with HIV-1ADA,
HIV-1JR-FL, or HIV-1BAL in the presence or absence of AZT. Cells (total RNA) and culture supernatants were collected 5 days after infection. A.
Supernatants were tested for HIV-1 RTase activity. B. TRAIL expression was determined by real-time RT-PCR. Results were normalized to GAPDH
expression and shown as fold change over control. ** indicates p,0.01 when compared to control; ## indicates p,0.01 when compared to
corresponding HIV-1 group. C–F. Human MDM were infected with HIV-1ADA. Samples were collected 1, 3, 5, and 7 days after infection. C. Supernatants
were tested for RTase activity. D. TRAIL expression was determined by real-time RT-PCR. E–F. TRAIL protein levels in cell lysate (E) and culture
supernatants (F) were measured by TRAIL ELISA. Open bars represent control MDM and solid bars represent HIV-1-infected MDM. ** indicates p,0.01,
* indicates p,0.05 when compared to the corresponding control. Data are representative of three donors.
doi:10.1371/journal.pone.0005397.g001
HIV-1, TRAIL, and Macrophage
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siRNA (Fig. 4A). The transfection efficiency, measured by
counting FAM-positive cells within 200 total cells, was approxi-
mately ,70% for both control and HIV-1-infected MDM. The
levels of IRF-1, IRF-3, and IRF-7 following siRNA delivery in
HIV-1-infected macrophages were 33%, 14%, and 28% of non-
specific siRNA-transfected HIV-infected MDM, respectively
(Fig. 4B–D). STAT1 phosphorylation was significantly reduced
after IRF-1 or IRF-7 knockdown in HIV-infected MDM, but was
unchanged after IRF-3 knockdown when compared with control
siRNA (Fig. 4E). Similarly, TRAIL expression levels remained
unchanged after IRF-3 siRNA transfection, but were significantly
reduced after IRF-1 siRNA transfection and were blocked by IRF-
7 siRNA transfection (Fig. 4F). The viral replication in each group
was monitored by the HIV-1 RTase activity assay. Knocking
down IRF-1 with siRNA decreased the HIV-1 infection levels,
whereas the IRF-7 knockdown increased HIV-1 infection levels.
Infection levels in IRF-3 knockdown remained unchanged
(Fig. 4G). These data demonstrate that IRF-1 and IRF-7 are
critical to the activation of STAT1 and the upregulation of TRAIL
expression in HIV-1-infected macrophages.
One unexpected finding in these IRF siRNA knockdown
experiments was that IRF-3 was not required for IFN induction. It
is well established that IRF3 is involved in IFN and IFN target
genes inductions [31]. We further analyzed the protein knockdown
of IRF-3 and found that the IRF-3 siRNA transfection reduced
IRF-3 protein level by 60% in HIV-1-infected MDM (Fig. S1A).
To further demonstrate the function of IRF-3 has been impaired
after IRF-3 knockdown, we tested CCL5, a chemokine whose
transcription is controlled by IRF-3 [44], and found that CCL5
was significantly downregulated after IRF-3 knockdown in HIV-1-
infected MDM(Fig. S1B). These data suggest that knocking down
IRF-3 is not sufficient to block HIV-1-induced STAT1 activation
and TRAIL expression.
IFNs potently increase macrophage TRAIL levels
Macrophages release various inflammatory cytokines such as
IL-1b and TNF-a upon HIV-1 infection [45,46]. We previously
reported LPS- and IFN-c-treated macrophages have higher levels
of cell-surface TRAIL through analysis by flow cytometry [10]. In
this study, we used quantitative TRAIL ELISA and evaluated
whether TRAIL synthesis by macrophages is mediated by
inflammatory cytokines, such as IL-1b and TNF-a. We treated
MDM with a panel of inflammatory cytokines and LPS. LPS has
been reported to increase both forms of TRAIL in MDM, and it
served as positive control in our TRAIL detection system [47].
TRAIL mRNA increased in response to LPS stimulation (Fig. 5A),
and TRAIL protein increased modestly in the cell lysates and
supernatants in response to LPS treatment (Fig. 5B, C). Treatment
of MDM with individual cytokines IL-1b (50 ng/ml) or TNF-a
(100 ng/ml) did not change membrane-bound or soluble TRAIL
protein levels nor were TRAIL mRNA levels affected. In contrast,
IFNs, including IFN-a, IFN-b, and IFN-c, caused a significant
increase in TRAIL protein and mRNA levels (Fig. 5A–C).
Macrophages do not typically produce type II IFNs, thus type I
IFNs remained the focus of our investigation.
Increased TRAIL expression in HIV-1-infected
macrophages is dependent on type I IFN activity
STAT1 activation is essential for the cells to response to type I
IFNs [48,49]. STAT1 activation in MDM by HIV-1-infection
suggests there are type I IFNs in the culture supernatant acting in
autocrine and paracrine manner. To test whether type I IFNs were
responsible for STAT1 activation and the subsequent increase in
TRAIL levels after HIV-1-infection of MDM, type I IFN-
neutralizing antibodies were administered. The type I IFN-
neutralizing antibodies worked effectively because inhibition of
IFN-a-induced STAT1 phosphorylation was found to be 92% for
IFN-a-neutralizing antibodies, and inhibition of IFN-b-induced
STAT1 phosphorylation (54%) were observed by IFN-b-neutral-
izing antibodies (Fig. 6A). In addition, TRAIL expression was
reduced by 97% and 79% after the treatment with the IFN-a- or
IFN-b-neutralizing antibodies, respectively (Fig. 6B). We then
added type I IFN-neutralizing antibodies to HIV-1-infected MDM
every 24 hours after HIV-1 infection until the fifth day. The
Figure 2. Membrane-bound TRAIL increases in HIV-1-infected macrophage culture. Human MDM were infected with HIV-1 for 5 days and
then stained with antibodies to p24 (HIV-1 infection marker, green) and TRAIL (red). Nuclei (blue) were labeled with Hoechst 33342. A–D. Control
uninfected MDM. E–H. HIV-1-infected MDM. Panels D and H are merged pictures of A–C and E–G, respectively. Images were acquired from a Bio-Rad
MRC1024ES LASER scanning confocal microscope. Magnifications: A–H. 6006. Panels are representative of 4 separate donors.
doi:10.1371/journal.pone.0005397.g002
HIV-1, TRAIL, and Macrophage
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neutralizing antibodies did not appear to change the RTase
activity, but partially blocked HIV-1-stimulated STAT1 phos-
phorylation (54% inhibition, Fig. 6C). Moreover, membrane-
bound TRAIL and TRAIL levels were reduced by the neutralizing
antibodies as compared to IgG control antibody (Fig. 6D, E). The
addition of neutralizing antibodies against type I IFNs partially
blocked HIV-1-induced IRF-1 and IRF-7 expression (Fig. 6F, G).
These data further support the hypothesis that increased IRF-1,
IRF-7, and TRAIL expression after HIV-1 infection is reliant on
type I IFNs.
To validate type I IFNs were the diffusible factors that regulated
TRAIL, we transferred supernatant from HIV-1-infected MDM to
uninfected MDM. Exposure of control MDM to HIV-1-infected
supernatants for 2 hours led to a dramatic activation of STAT1
similar to that seen in HIV-1-infected MDM (Figs. 3 and 6I).
Because binding of HIV-1 virions or gp120 may also activate
STAT1, we used centrifugal filters with 100 kDa molecular weight
pores to separate HIV-1 virions and gp120 from lower molecular
weight compounds. After filtration, HIV-1 RTase activity was
completely lost (data not shown), suggesting successful removal of
virions. The lower molecular weight fraction after filtration
induced strong STAT1 phosphorylation (Fig. 6H), confirming
diffusible factors (,100 kDa) are capable of activating STAT1.
Interestingly, IFN-a-neutralizing antibody reduced STAT1 acti-
vation (48% inhibition) and significantly reduced TRAIL
expression levels, whereas IFN-b-neutralizing antibody treatment
Figure 3. HIV-1 infection induces IRF-1 and IRF-7 gene expression and STAT1 phosphorylation at Tyr701 in macrophages.MDM were
infected with HIV-1 and cell lysates and RNA were collected 1, 3, 5, and 7 days after infection. A–C. Real-time RT-PCR was used to detect IRF-1 (A), IRF-
3 (B), and IRF-7 (C). Open bars represent control MDM and solid bars represent HIV-1-infected MDM. IFN-a (1000 Units/ml) was also used to stimulate
MDM for 24 hours, the effect on IRFs expression is shown in each panel as the diagonal striped bar. D. Phospho-STAT1 (p-STAT1, Tyr701) and total
STAT1 were detected by Western blotting. b-actin was used as a loading control. E. Levels of p-STAT1 were normalized as a ratio of p-STAT1 to STAT1
after densimetrical quantification of panel D and shown as fold change relative to control (1 dpi). F. Levels of STAT1 were normalized as a ratio of
STAT1 to b-actin and shown as fold change relative to control (1 dpi). Results are shown as the average6SEM in experiments performed with three
different donors. *, p,0.05 compared with day-matched control. **, p,0.01 compared to day-matched control.
doi:10.1371/journal.pone.0005397.g003
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did not cause a statistically significant decrease in STAT1
activation or TRAIL expression (Fig. 6I, J). These data
demonstrate that type I IFNs, likely IFN-a, is released by
macrophages upon HIV-1 infection resulting in increased TRAIL
levels.
STAT1 is essential for IRFs and TRAIL expression in HIV-1-
infected macrophages
We next determined whether STAT1 modulates HIV-1-
induced TRAIL expression in MDM. Fludarabine, a compound
that has been shown to specifically inhibit STAT1 activation and
induce loss of STAT1 mRNA and proteins [50], was used to block
HIV-1-mediated STAT1 activation. When used at 1 mM,
fludarabine abolished HIV-1-induced phosphorylation of STAT1
as well as HIV-1-induced increase in total STAT1 (Fig. 7A).
Accordingly, HIV-1-induced gene expression of TRAIL (Fig. 7B),
IRF-1 (Fig. 7C), and IRF-7 (Fig. 7D) were completely blocked by
fludarabine treatment. These results suggest that STAT1 is
essential for IRF-1, IRF-7, and TRAIL expression in HIV-1-
infected macrophages.
Discussion
The molecular mechanisms of TRAIL induction by HIV-1 in
macrophages are not completely understood. Here we investigated
the regulation of TRAIL as well as the upstream molecular events
responsible for TRAIL induction in HIV-1-infected macrophages.
We demonstrated that upregulation of TRAIL expression in HIV-
1-infected MDM was predominantly membrane-associated (Fig. 1,
2). HIV-1 infection induced IRF-1, IRF-7 gene expression and
activated STAT1 in macrophages (Fig. 3). IRF-1 and IRF-7
promoted Type I IFNs production and subsequent STAT1
activation (Fig. 4). Type I IFNs and STAT1 activation further
increased IRF-1 and IRF-7 gene expression (Fig. 6, 7). Blocking
signaling factors, including IRF-1, IRF-7, type I IFNs, or STAT1,
significantly reduced TRAIL gene expression (Fig. 4, 6, 7). These
data provide insight to the detailed regulation of TRAIL and
identify IRF-1, IRF-7, type I IFNs, and STAT1 as critical
signaling intermediates for TRAIL induction. Although IRFs have
been reported to regulate type I IFNs, we were surprised to find
that IRF-3 is not as critical as IRF-1 or IRF-7 in the signaling
cascade (Fig. 4). Instead, a positive feedback loop between
intracellular IRF1, IRF-7, STAT1 and soluble type I IFNs exists
and cooperatively regulates TRAIL in HIV-1-infected macro-
phages (see scheme in Fig. 8).
We [10,11], as well as others [6–9] have identified TRAIL-
induced apoptosis in several cell types during HIV-1 infection.
The exact pathological consequences of the increased membrane-
bound TRAIL in macrophages and in other cell types remain to
be established. Given that TRAIL preferentially kills HIV-1-
infected macrophages, it is plausible that the initial increase in
TRAIL is part of the innate immune response directed toward the
elimination of HIV-1-infected cells. Other unexpected target of
TRAIL, particularly uninfected CD4+ T cells, may add to the
complexity of TRAIL-mediated cell death. The increased
membrane-bound form of TRAIL in macrophages may team
together with either membrane-bound or soluble form of TRAIL
in monocytes and CD4+ T cells, possibly causing apoptosis of
bystander CD4+ T cells. This adverse effect of TRAIL on the
adaptive immune system during HIV-1 infection may help to
explain why HIV-1 persists even in the presence of elevated
soluble and membrane-bound TRAIL.
Members of the IRF family are important antiviral transcription
factors. IRF-3 and IRF-7 participate in immune responses and are
primarily associated with Type I IFNs [30–32]. In addition, IRF-1,
IRF-5, and IRF-8 can also contribute to type I IFNs induction (for
review, see [51]). Increased IRF-1 expression has been reported in
HIV-1-infected Jurkat and primary CD4+ T cells [52]. IRF-7 is
increased in HIV-1-infected individuals in plasmacytoid dendritic
cells, another mononuclear phagocyte cell type and the major
IFN-producing cells [36]. However, limited information on the
regulation and function of IRFs in HIV-1-infected macrophages
has been reported to date. Our data show increased IRF-1 and
IRF-7 expression in HIV-1-infected macrophages (Fig. 3), and that
IRF-7 knockdown in macrophages facilitated HIV-1 replication
(Fig. 4F), highlighting the importance of IRF-7 in the antiviral
response of macrophages. In contrast, knockdown of IRF-1
inhibited HIV-1 replication (Fig. 4F). The difference between
IRF-1 and IRF-7 on HIV-1 replication may be due to the
requirement of IRF-1, but not IRF-7, for full NF-kB transcrip-
tional activity at the HIV-1 long term repeat enhancer [53]. The
unique roles of IRF-1 in the enhancement of HIV-1 replication
and induction of death ligand TRAIL provide a potentially novel
therapeutic target, and inhibition of IRF-1 may simultaneously
reduce HIV-1 viral load and alleviate macrophage-mediated HIV-
1 pathogenesis.
IRF-1 and IRF-3 have been shown to regulate TRAIL
transcription in tumor cell lines [38–40]. More recently,
overexpression of IRF-7 has been found to enhance TRAIL
transcription in macrophages [41]. When we applied siRNA to
knockdown IRF-1, IRF-3, or IRF-7 gene expression in human
macrophages, the increase of TRAIL expression by HIV-1
infection was reduced by the IRF-1 and the IRF-7 knockdown,
but not by the IRF-3 knockdown (Fig. 4G). This is, to the best of
our knowledge, the first report of IRFs knockdown in HIV-1-
infected macrophages. Knockdown of IRF-1 and IRF-7 reduced
STAT1 phosphorylation, an essential component for type I IFNs
responsiveness (Fig. 4E). However, type I IFNs-neutralizing
antibodies did not completely block TRAIL upregulation in
HIV-1-infected culture (Fig. 6D, E), suggesting the involvement of
a type I IFNs-independent pathway in the induction of TRAIL.
These type I IFNs-dependent and -independent mechanisms may
work concomitantly in HIV-1-infected culture to induce TRAIL
expression. Our analysis also found that IRF-5 gene expression
could be induced upon HIV-1 infection in macrophages but in
lower abundance. In addition, IRF-8 gene expression was not
induced by HIV-1 infection but was expressed at a higher amount.
Figure 4. siRNA knockdown of IRF-1 and IRF-7 reduces STAT1 phosphorylation and TRAIL expression in HIV-1-infected
macrophages. Two days after HIV-1 infection, MDM were transfected with siRNA for IRF-1, -3, or -7. A. Forty-eight hours later, successful
transfections were confirmed by Silencer FAM-labeled Negative Control #1 siRNA transfection indicator (green). Hoechst 33258 (nucleus marker,
blue) was used to visualize the total cell number. B–D. Total RNA was collected 48 hours post-transfection and mRNA levels of IRF-1(B), -3(C), or -7(D)
were determined by real-time RT-PCR. E. Ninety-six hours after transfection, p-STAT1 and total STAT1 were detected by Western blotting. b-actin was
used as a loading control. F. TRAIL expression levels were determined by real-time RT-PCR. Results were normalized with GAPDH and shown as the
fold change over non-specific siRNA control. G. Supernatants were tested for HIV-1 RTase activity. ** indicates p,0.01 when compared to control; #
indicates p,0.05 when compared to HIV group with siRNA control; ## indicates p,0.01 when compared to HIV group with siRNA control. Data are
representative of three donors.
doi:10.1371/journal.pone.0005397.g004
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The role of these additional members of IRFs in the type I IFNs
production and TRAIL regulation remains to be elucidated.
The upstream molecular mechanisms resulting in the activation
of IRF-1 and IRF-7 during viral infection have begun to be
elucidated in recent years. Toll-like receptors (TLRs) and RIG-I-
like receptors are two separate classes of pattern-recognition
receptors (PRRs) that detect viral infection and initiate signaling
cascades including IRFs and type I IFNs (for review, see [54]).
However, TLR signaling cascade, which can be activated in
plasmacytoid dendritic cells, fails to promote activation in
macrophages in response to HIV-1 [55]. We suspect that other
viral sensing pathways may lead to IRFs activation in HIV-1-
infected macrophages. We tested RIG-I, a TLR-independent
PRRs, and found that HIV-1 infection increased RIG-I protein
levels, and the increase occurred as early as one day after infection
(Fig. S2). Activation of RIG-I leads to a signaling results in the
activation of IRF-3 and IRF-7 [56–58]. Furthermore, melanoma
differentiation-associated gene 5, another RIG-I like receptor, has
been reported to activate IRF-1, -3, and -7 [57,59]. Despite our
extensive studies, we cannot exclude the potential roles of TLRs in
the regulation of IRF-1 and IRF-7 during HIV-1 infection. The
upregulation of RIG-I by HIV-1 infection in macrophages is novel
and interesting, however its relationship with IRF-1 and IRF-7
regulation remains the subject of further investigation.
Recently HIV-1 accessory proteins, VPR and Vif, have been
reported to degrade IRF-3 through ubiquitin-associated proteo-
some pathway [60]. If IRF-3 degradation occurred in our HIV-1-
infected MDM culture, it could skew the interpretations of our
current results. To discount this, we have tested the IRF-3 protein
levels by Western blotting and found no dramatic degradation of
IRF-3 in our MDM during the HIV-1 infection course (data not
shown). In fact, there is a transient increase of IRF-3 at 5 days post
HIV-1 infection (Fig. S1A). This is more comparable with a
previous publication, which showed neither degradation nor
activation of IRF-3 in HIV-1-infected macrophages [55]. This
inconsistency in the literature may be explained by the differences
in cellular models and stages of HIV-1 infection. In addition, a cell
type-specific role for IRF-1 to supplant the requirement for IRF-3
in macrophages has been reported recently [61]. Whether
upregulation of IRF-1 and IRF-7 could potentially restore the
function of IRF-3 awaits future investigation.
Our results identify type I IFNs as a critical component of the
signaling cascade regulating TRAIL expression. In HIV-1
infection, type I IFNs are produced mainly by plasmacytoid
dendritic cells and in lower amounts by monocytes and
macrophages [23,24,62]. Interestingly, type I IFNs have been
tested in clinical trials for HIV-1 treatment and resulted in a
transiently decreased viral load and increased hematologic toxicity
and peripheral neuropathy [63]. Although type I IFNs activate
macrophages and improve the immune function of macrophages,
our data found endogenous type I IFNs do not significantly
decrease viral replication in infected MDM cultures (data not
shown). This contradiction suggests that there is a complex
interaction between HIV-1 and macrophages, where the innate
immune response may contribute to viral replication.
Figure 5. IFNs are potent stimulators of TRAIL expression in
macrophages. Human MDM were infected with HIV-1 or stimulated
with different inflammatory cytokines IL-1b (50 ng/ml), TNF-a (100 ng/
ml), IFN-a (1000 Units/ml), IFN-b (1000 Units/ml), IFN-c (100 ng/ml), or
LPS (100 ng/ml). Cell lysates and culture supernatants were either
collected 5 days following HIV-1 infection or 24 hours following
stimulation. A. TRAIL expression was determined by real-time RT-PCR.
B–C, TRAIL protein levels in cell lysate and culture supernatants were
measured by ELISA. * indicates p,0.05, ** indicates p,0.01 when
compared to control. Data are representative of three donors.
doi:10.1371/journal.pone.0005397.g005
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STAT1 activation in HIV-1-infected MDM and peripheral
blood mononuclear cells has been reported and correlated with
HIV pathogenesis [64,65]. STAT1 activation seems to primarily
be involved in the response to type I and II IFNs and involves
phosphorylation of Tyr 701 and/or Ser727 [48,49]. Tyr701 is
obligatory for STAT1 activation, while Ser727 may be required
for the maximal induction of STAT1-mediated gene activation
[26,66]. We have demonstrated that HIV-1 infection increased
STAT1 phosphorylation at Tyr701 and total STAT1 expression
(Fig. 3) and that the activation of STAT1 is essential for IRF-1 and
IRF-7 expression and TRAIL induction (Fig. 7). The potential
mechanism(s) linking upstream STAT1 activation to IRF-1 and
IRF-7 is not investigated in the current study. The activation of
STAT1 could directly bind to the IRF-1 or IRF-7 promoter and
turn on gene transcription [67–69]. Moreover, a reciprocal build
up between IRF and IFN in the later stages of infection may
contribute to the changes of gene expression and STAT1
activation. In addition, it should be noted that other cytokines
such as epidermal growth factor, platelet-derived growth factor,
and interleukin-6, along with HIV-1 virions and viral proteins
such as gp120, Tat, and Nef may be secreted by HIV-1-infected
macrophages thereby mediating type I IFNs production or
STAT1 activation [7,8,65,70–72]. Nevertheless, our data strongly
support a critical role for IRF-1, IRF-7, and type I IFNs in the
induction of macrophage STAT1 activation during HIV-1
infection.
Biologically active forms of TRAIL include membrane-bound
TRAIL and soluble TRAIL [4,28,73]. In our study, both
Figure 6. Type I interferon from HIV-1-infected macrophages induces STAT1 phosphorylation, IRF-1, IRF-7, and TRAIL expression.
A. MDM were treated with IFN-a (1000 Units/ml) or IFN-b (1000 Units/ml) with or without their corresponding neutralizing antibodies. Cell lysates
were collected 2 hours later and subjected to Western blotting for p-STAT1 and STAT1. b-actin was used as a loading control. B. 24 hours after the
treatment, TRAIL expression was determined by real-time RT-PCR. ** denotes p,0.01 compared with IgG control; ## indicates p,0.01 compared
with the corresponding IFN group. Experiments are representative of duplicate assays from two different donors. C–G. Human MDM were infected
with HIV-1 for 5 days with or without type I IFNs-neutralizing antibodies and total RNA and cell lysates were collected. C. Cell lysates were subjected
to Western blotting for p-STAT1 and STAT1. D. TRAIL expression was determined by real-time RT-PCR. E. TRAIL protein levels in cell lysates were
detected by ELISA. Experiments are representative of three different donors. *, p,0.05 compared with neutralizing antibodies treatment. F–G. IRF-
1(F) and IRF-7(G) expression were determined by real-time RT-PCR. Results were shown as the average6SEM in experiments performed with three
different donors. H. Supernatants from HIV-1 culture were collected 5 days after infection and filtered with 100 k centrifugal filter device. The flow-
through was transferred to control MDM for 2 hours and STAT1 phosphorylation was determined by Western blotting. I. Supernatants from HIV-1
culture were transferred to control MDM culture with or without IFN-a- or IFN-b- neutralizing antibodies. Cell lysates were collected 2 hours later and
subjected to Western blotting for p-STAT1 and STAT1. J. Twenty-four hours after the treatment, TRAIL expression was determined by real-time RT-
PCR. ** indicates p,0.01 when compared to IgG control; #, p,0.05, ##, p,0.01 compared with IgG/HIV-1 group.
doi:10.1371/journal.pone.0005397.g006
Figure 7. Fludarabine blocks HIV-1-induced STAT1 activation and gene expression of IRF-1, IRF-7, and TRAIL in macrophages. A.
MDM were treated with fludarabine at 1 mM 3 days after infection. P-STAT1 and total STAT1 were detected by Western blotting at 5 days after
infection. b-actin was used as a loading control. B–D. Real-time RT-PCR was used to detect TRAIL (B), IRF-1 (C), and IRF-7 (D). **, p,0.05 compared
with DMSO control. ##; p,0.01 compared to DMSO-treated HIV-1 group.
doi:10.1371/journal.pone.0005397.g007
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transcription and membrane-bound levels of TRAIL were
significantly increased in HIV-1-infected or IFN-treated MDM
but not by inflammatory cytokines TNF-a- or IL-1b-mediated
activation (Fig. 5). Notably, soluble TRAIL was secreted by
macrophages following type I interferon treatment but not by
HIV-1-infected macrophages (Fig. 1). This is consistent with a
previous report that there was no soluble TRAIL production upon
exposure to HIV-1 [5]. The low production of soluble TRAIL
despite the dramatic increase of transcription and membrane-
bound TRAIL is probably cell type-specific and the regulation
mechanisms warrants future investigation.
In summary, our current study revealed the signaling mecha-
nisms of TRAIL upregulation in HIV-1-infected macrophages.
The role of IRF-1, IRF-7, type I IFNs, and STAT1 in the
regulation of TRAIL during HIV-1 infection of macrophages is
important and adds to our understanding of pathogenesis of HIV-
1. Identifying cytotoxicity in the antiviral response to type I IFNs
and its signaling mechanism would potentially provide targets for
therapeutic interventions for HIV-1 infection.
Supporting Information
Figure S1 siRNA knockdown of IRF-3 reduces CCL5 produc-
tion in HIV-1-infected macrophages. Two days after HIV-1
infection, MDM were transfected with siRNA for IRF-3. A.
Ninety-six hours after transfection, IRF-3 was detected by Western
blotting. b-actin was used as a loading control. Levels of IRF-3
were normalized as a ratio of IRF-3 to b-actin after densimetrical
quantification and shown as fold change relative to non-specific
siRNA control. B. CCL5 levels were determined by ELISA. **
indicates p,0.01 when compared to non-specific siRNA control;
## indicates p,0.01 when compared to HIV group with siRNA
control. Data are representative of three donors.
Found at: doi:10.1371/journal.pone.0005397.s001 (0.85 MB
DOC)
Figure S2 Infection with HIV-1 induces an increase of RIG-I in
macrophages. MDM were infected with HIV-1 and cell lysates
were collected 1, 3, 5, and 7 days after infection. RIG-I was
detected by Western blotting and b-actin was used as a loading
control. Levels of RIG-I were normalized as a ratio of RIG-I to b-
actin after densimetrical quantification and shown as fold change
relative to control (1 dpi). Results are shown as the average6SEM
in experiments performed with five different donors. *, p,0.05
compared with day-matched control. **, p,0.01 compared to
day-matched control.
Found at: doi:10.1371/journal.pone.0005397.s002 (0.72 MB TIF)
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